部門紹介

研究業績

最終更新日 : 2019年12月16日

目次

  1. 原著論文
  2. 解説・総説や教科書など

原著論文

2019年

Yuasa T..
Editorial comment to Possible abscopal effect in urothelial carcinoma of the upper urinary tract after treatment with immune checkpoint inhibitors. IJU Case Reports. 2019 (in press).
Yuasa T..
Editorial comment to The clinicopathological features of malignant urachal tumor: A hospital-based cancer registry data in Japan. Int J Urol. 2019 (in press).
Yuasa T..
Editorial comment to Syndrome of inappropriate antidiuretic hormone secretion as a side effect of chemotherapy for testicular cancer: report of a case. Int J Urol. 2019 (in press).
Fujiwara R, Inamura K, Yuasa T., Numao N, Yamamoto S, Masuda H, Kawauchi A, Takeuchi K, Yonese J.
Efficacy and safety profile of nivolumab for Japanese patients with metastatic renal cell cancer. Int J Clin Oncol. 2019 Sep 14. doi: 10.1007/s10147-019-01542-7.
Yasuoka S, Yuasa T., Ogawa M, Komai Y, Numao N, Yamamoto S, Kondo Y, Yonese J.
Risk Factors for Poor Survival in Metastatic Castration-resistant Prostate Cancer Treated With Cabazitaxel in Japan. Anticancer Res. 2019 Oct;39(10):5803-5809. doi: 10.21873/anticanres.13784.
Yasuoka S, Yuasa T.., Nishimura N, Ogawa M, Komai Y, Numao N, Yamamoto S, Kondo Y, Yonese J.
Initial Experience of Pembrolizumab Therapy in Japanese Patients With Metastatic Urothelial Cancer. Anticancer Res. 2019 Jul;39(7):3887-3892. doi: 10.21873/anticanres.13539.
Yuasa T..
Editorial Comment to Comparison of the predictive value among inflammation-based scoring systems for bleomycin pulmonary toxicity in patients with germ cell tumors. Int J Urol. 2019 May 26. doi: 10.1111/iju.14030.
Yuasa T..
Editorial Comment to Docetaxel-based chemotherapy combined with dexamethasone 1 mg daily oral administration for castration-resistant prostate cancer: Long-term outcomes. Int J Urol. 2019 May 12. doi: 10.1111/iju.14018.
Isono T, Chano T, Yoshida T, Makino A, Ishida S, Suzaki M, Kageyama S, Kawauchi A, Yonese J, Yuasa T..
ADP-ribosylation factor-like 4C is a predictive biomarker of poor prognosis in patients with renal cell carcinoma. Am J Cancer Res 2019;9:415-423.
Dudani S, Graham J, Wells JC, Bakouny Z, Pal SK, Dizman N, Donskov F, Porta C, de Velasco G, Hansen A, Iafolla M, Beuselinck B, Vaishampayan UN, Wood LA, Liow E, Yan F, Yuasa T., Bjarnason GA, Choueiri TK, Heng DYC.
First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium. Eur Urol. 2019 Aug 22. pii: S0302-2838(19)30609-8. doi: 10.1016/j.eururo.2019.07.048. [Epub ahead of print]
Inamura K, Amori G, Yuasa T., Yamamoto S, Yonese J, Ishikawa Y.
Relationship of B7-H3 expression in tumor cells and tumor vasculature with FOXP3+ regulatory T cells in renal cell carcinoma. Cancer Management and Research 2019, 11:7021-7030
Fujiwara R, Numao N, Ishikawa Y, Inoue T, Ogawa M, Masuda H,Yuasa T., Yamamoto S, Fukui I, Yonese J.
Incidence and Predictors of Deep Vein Thrombosis in Patients with Elevated Serum D-Dimer Prior to Surgery for Urologic Malignancy. Urol Int. 2019 Aug 28:1-6. doi: 10.1159/000502660.
Stukalin I, Wells JC, Graham J, Yuasa T., Beuselinck B, Kollmansberger C, Ernst DS, Agarwal N, Le T, Donskov F, Hansen AR, Bjarnason GA, Srinivas S, Wood LA, Alva AS, Kanesvaran R, Fu SYF, Davis ID, Choueiri TK, Heng DYC. 
Real-world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium. Curr Oncol. 2019 Apr;26(2):e175-e179. doi: 10.3747/co.26.4595.
Yokoyama M, Kusano Y, Nishihara A, Inoue N, Nishimura N, Mishima Y, Terui Y, Nukada T, Nomura T, Hatake K.
Incidence and risk factors for febrile neutropenia in Japanese patients with non-Hodgkin B cell lymphoma receiving R-CHOP: 2-year experience in a single center (STOP FN in NHL 2).
Support Care Cancer. 2019 May 15. doi: 10.1007/s00520-019-04802-4. (2019)

このページのTOPへ

2018年

Yip SM, Wells C, Moreira R, Wong A, Srinivas S, Beuselinck B, Porta C, Sim HW, Ernst DS, Rini BI, Yuasa T., Basappa NS, Kanesvaran R, Wood LA, Canil C, Kapoor A, Fu SYF, Choueiri TK, Heng DYC.
Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the international metastatic renal cell carcinoma database consortium. Cancer. 2018 Sep 15;124(18):3677-3683.
Isono T, Chano T, Yoshida T, Kageyama S, Kawauchi A, Yonese J, Yuasa T..
Abundance of TRAIL attenuated by HIF2α and c-FLIP affects malignancy in renal cell carcinomas. Oncotarget. 2018 May 1;9(33):23091-23101. doi: 10.18632/oncotarget.25214. eCollection 2018 May 1.
Yoshida T, Kageyama S, Isono T, Yuasa T., Kushima R, Kawauchi A, Chano T.
Superoxide dismutase 2 expression can predict prognosis of renal cell carcinoma patients. Cancer Biomark. 2018;22(4):755-761. doi: 10.3233/CBM-181308.
Komai Y, Gotohda N, Matsubara N, Takeda H, Yuasa T., Inoue M, Yamamoto S, Yonese J.
Preliminary kidney parenchymal ligation using Endoloop® ligatures-A simple method to achieve a trifecta in laparoscopic partial nephrectomy without hilar clamping for polar complex tumors. Urology. 2018 121:182-188. doi: 10.1016/j.urology.2018.08.023.
Yuasa T., Urakami S, Yonese J.
Recent advances in medical therapy for metastatic urothelial cancer. Int J Clin Oncol. 2018 Aug;23(4):599-607. doi: 10.1007/s10147-018-1260-0.
Yuasa T..
Editorial comment to Prognostic impact of the pretreatment aspartate transaminase/alanine transaminase ratio in patients treated with tyrosine kinase inhibitors as a first-line therapy for metastatic renal cell carcinoma. Int J Urol 2018 Jun;25(6):604-605.
Kusano Y, Yokoyama M, Inoue N, Yamauchi H, Takahashi A, Tsuyama N, Mishima Y, Nishimura N, Takeuchi K, Terui Y, Hatake K.
Delayed recovery of serum immunoglobulin G is a poor prognostic marker in patients with follicular lymphoma treated with rituximab maintenance.
Ann Hematol. 2018 Feb;97(2):289-297. (2018 )

このページのTOPへ

2017年

Yuasa T., Masuda H, Yamamoto S, Numao N, Yonese J.
Biomarkers to predict prognosis and response to checkpoint inhibitors. Int J Clin Oncol. 2017 Aug;22(4):629-634. doi: 10.1007/s10147-017-1122-1.
Yip SM, Ruiz Morales JM, Donskov F, Fraccon A, Basso U, Rini BI, Lee JL, Bjarnason GA, Sim HW, Beuselinck B, Kanesvaran R, Brugarolas J, Koutsoukos K, Fu SYF, Yuasa T., Davis I, Alva A, Kollmannsberger C, Choueiri TK, Heng DYC.
Outcomes of Metastatic Chromophobe Renal Cell Carcinoma (chrRCC) in the Targeted Therapy Era: Results from the International Metastatic Renal Cell Cancer Database Consortium (IMDC). Kidney Cancer. 2017 Jul 26;1(1):41-47. doi: 10.3233/KCA-160002.
Uehara S, Yuasa T., Fujisaki J, Fujii Y, Yamamoto S, Masuda H, Fukui I, Yonese J.
A case of gastric metastasis from renal cell cancer during the sequential targeted therapy. Int Cancer Conf J. 2017 July:6(3) 114-7
Yuasa T..
Editorial comment to Identification of risk factors predicting febrile neutropenia in patients with metastatic germ cell tumors receiving cisplatin-based combination chemotherapy. Int J Urol 2017 Jun;24(6):453. doi: 10.1111/iju.13365
Yasuda Y, Saito K, Yuasa T., Uehara S, Kawamura N, Yokoyama M, Ishioka J, Matsuoka Y, Yamamoto S, Okuno T, Yonese J, Kihara K, Fujii Y.
Early response of C-reactive protein as a predictor of survival in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol. 2017 Dec;22(6):1081-1086.doi: 10.1007/s10147-017-1166-2.
Tanaka H, Fujii Y, Tanaka H, Ishioka J, Matsuoka Y, Saito K, Uehara S, Numao N, Yuasa T., Yamamoto S, Masuda H, Yonese J, Kihara K.
Stepwise algorithm using computed tomography and magnetic resonance imaging for diagnosis of fat-poor angiomyolipoma in small renal masses: Development and external validation. Int J Urol. 2017 Jul;24(7):511-517. doi: 10.1111/iju.13354.
Koizumi M, Motegi K, Koyama M, Terauchi T, Yuasa T., Yonese J.
Diagnostic performance of a computer-assisted diagnosis system for bone scintigraphy of newly developed skeletal metastasis in prostate cancer patients: search for low-sensitivity subgroups. Ann Nucl Med. 2017 Aug;31(7):521-528. doi: 10.1007/s12149-017-1175-2.
Davis ID, Xie W, Pezaro C, Donskov F, Wells JC, Agarwal N, Srinivas S, Yuasa T., Beuselinck B, Wood LA, Ernst DS, Kanesvaran R, Knox JJ, Pantuck A, Saleem S, Alva A, Rini BI, Lee JL, Choueiri TK, Heng DY.
Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category. Eur Urol. 2017 Jun;71(6):970-978. doi: 10.1016/j.eururo.2016.09.047.
K. Hosoya, S. Matsusaka, T. Kashiwada, K. Suzuki, N. Ureshino, A. Sato, Y. Miki, K. Kitera, M. Hirai, K. Hatake, S. Kimura and N. Sueoka-Aragane.
Detection of KRAS mutations in plasma DNA using a fully automated Rrpid detection system in colorectal cancer patients.
Pathol. Oncol. Res., in press (2017)
Mishima Y, Terui Y, Yokoyama M, Nishimura N, Ueda K, Kusano Y, Yamauchi H, Inoue N, Takahashi A, Tsuyama N, Mishima Y, Takeuchi K, Hatake K.
Bearing 19q13 aberration predicts poor prognosis in non-germinal centre type of CD5+ DLBCL.
Br J Haematol. doi: 10.1111/bjh.15001. [Epub ahead of print] No abstract available. (2017)
Yokoyama M, Kusano Y, Takahashi A, Inoue N, Ueda K, Nishimura N, Mishima Y, Terui Y, Nukada T, Nomura T, Hatake K.
Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan.
Support Care Cancer. 2017 Nov;25(11):3313-3320. (2017)
Tsuyama N, Sakata S, Baba S, Mishima Y, Nishimura N, Ueda K, Yokoyama M, Terui Y, Hatake K, Kitagawa M, Ishizuka N, Tomita N, Takeuchi K.
BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation.
Blood. 130(4):489-500. (2017)
Mishima Y, Matsusaka S, Chin K, Mikuniya M, Minowa S, Takayama T, Shibata H, Kuniyoshi R, Ogura M, Terui Y, Mizunuma N, Hatake K.
Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients.
Target Oncol. 12(3):341-351. (2017)
Tsuyama N, Ennishi D, Yokoyama M, Baba S, Asaka R, Mishima Y, Terui Y, Hatake K, Takeuchi K.
Clinical and prognostic significance of aberrant T-cell marker expression in 225 cases of de novo diffuse large B-cell lymphoma and 276 cases of other B-cell lymphomas.
Oncotarget. 8(20):33487-33500. (2017)
Mishima Y, Terui Y, Yokoyama M, Nishimura N, Ueda K, Kusano Y, Yamauchi H, Inoue N, Takahashi A, Tsuyama N, Mishima Y, Takeuchi K, Hatake K.
Bearing 19q13 aberration predicts poor prognosis in non-germinal centre type of CD5+ DLBCL.
Br J Haematol. doi: 10.1111/bjh.15001. (2017)
Yokoyama M, Kusano Y, Takahashi A, Inoue N, Ueda K, Nishimura N, Mishima Y, Terui Y, Nukada T, Nomura T, Hatake K.
Incidence and risk factors of febrile neutropenia in patients with non-Hodgkin B-cell lymphoma receiving R-CHOP in a single center in Japan.
Support Care Cancer. 2017 Nov;25(11):3313-3320. (2017)
Tsuyama N, Sakata S, Baba S, Mishima Y, Nishimura N, Ueda K, Yokoyama M, Terui Y, Hatake K, Kitagawa M, Ishizuka N, Tomita N, Takeuchi K.
BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation.
Blood. 130(4):489-500. (2017)
Mishima Y, Matsusaka S, Chin K, Mikuniya M, Minowa S, Takayama T, Shibata H, Kuniyoshi R, Ogura M, Terui Y, Mizunuma N, Hatake K.
Detection of HER2 Amplification in Circulating Tumor Cells of HER2-Negative Gastric Cancer Patients.
Target Oncol. 12(3):341-351. (2017)
Sugihara T, Koizumi M, Koyama M, Terauchi T, Gomi N, Ito Y, Hatake K, Sata N.
Bone metastases from breast cancer: associations between morphologic CT patterns and glycolytic activity on PET and bone scintigraphy as well as explorative search for influential factors.
Ann Nucl Med. 31(10):719-725. doi: 10.1007/s12149-017-1202-3. (2017)

このページのTOPへ

2016年

Isono T, Chano T, Yoshida T, Kageyama S, Kawauchi A, Suzaki M,Yuasa T.:
Hydroxyl-HIF2-alpha is potential therapeutic target for renal cell carcinomas. Am J Cancer Res 2016;6(10):2263-2276. eCollection.
Shibata H, Kato S, Sekine I, Abe K, Araki N, Iguchi H, Izumi T, Inaba Y, Osaka I, Kato S, Kawai A, Kinuya S, Kodaira M, Kobayashi E, Kobayashi T, Sato J, Shinohara N, Takahashi S, Takamatsu Y, Takayama K, Takayama K, Tateishi U, Nagakura H, Hosaka M, Morioka H, Moriya T, Yuasa T., Yurikusa T, Yomiya K, Yoshida M.
Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology. ESMO Open. 2016 Mar 16;1(2):e000037.
Albiges L, Hakimi AA, Xie W, McKay RR, Simantov R, Lin X, Lee JL, Rini BI, Srinivas S, Bjarnason GA, Ernst S, Wood LA, Vaishamayan UN, Rha SY, Agarwal N, Yuasa T., Pal SK, Bamias A, Zabor EC, Skanderup AJ, Furberg H, Fay AP, de Velasco G, Preston MA, Wilson KM, Cho E, McDermott DF, Signoretti S, Heng DY, Choueiri TK.
Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations. J Clin Oncol. 2016 Sep 6. pii: JCO667311. [Epub ahead of print]
Yuasa T..
Editorial Comment to Role of routine computed tomography scan in the oncological follow up of patients treated by radical cystectomy for bladder cancer. Int J Urol. 2016 Oct;23(10):846-847. doi: 10.1111/iju.13178.
Yamasaki M, Yuasa T., Uehara S, Fujii Y, Yamamoto S, Masuda H, Fukui I, Yonese J.
Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab. Int J Clin Oncol. 2016 Dec;21(6):1191-1195.
Isono T, Chano T, Yonese J, Yuasa T..
Therapeutic inhibition of mitochondrial function induces cell death in starvation-resistant renal cell carcinomas. Sci Rep. 2016 May 9;6:25669. doi: 10.1038/srep25669.
Yamasaki M, Yuasa T., Yamamoto S, Hayashi T, Ogawa M, Sakura M, Masuda H, Fukui I, Yonese J.
Efficacy and Safety Profile of Enzalutamide for Japanese Patients with Castration-resistant Prostate Cancer. Anticancer Res. 2016 Jan;36(1):361-5.
Ruiz-Morales JM, Swierkowski M, Wells JC, Fraccon AP, Pasini F, Donskov F, Bjarnason GA, Lee JL, Sim HW, Sliwczynsk A, Ptak-Chmielewska A, Teter Z, Beuselinck B, Wood LA, Yuasa T., Pezaro C, Rini BI, Szczylik C, Choueiri TK, Heng DY.
First-line sunitinib versus pazopanib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur J Cancer. 2016;65:102-108. doi: 10.1016/j.ejca.2016.06.016.
Sano M, Yamamoto S, Uehara S, Yuasa T., Masuda H, Fukui I, Yonese J.
Long-term complete response of antiandrogen withdrawal syndrome in a patient with metastatic prostate cancer: A case report. Mol Clin Oncol. 2016 Sep;5(3):208-210. doi: 10.3892/mco.2016.946
Hayashi T, Yuasa T., Uehara S, Inoue Y, Yamamoto S, Masuda H, Fujii Y, Fukui I, Yonese J.
Clinical outcome of urachal cancer in Japanese patients. Int J Clin Oncol. 2016 Feb;21(1):133-8.
Tanaka H, Yoshida S, Komai Y, Sakai Y, Urakami S, Yuasa T., Yamamoto S, Masuda H, Koizumi M, Kohno A, Fukui I, Yonese J, Fujii Y, Kihara K.
Clinical Value of F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Upper Tract Urothelial Carcinoma: Impact on Detection of Metastases and Patient Management. Urol Int. 2016;96(1):65-72. doi: 10.1159/000381269.
A. Dobashi, N. Tsuyama, R. Asaka, Y. Togashi, K. Ueda, S. Sakata, S. Baba, K. Sakamoto, K. Hatake and K. Takeuchi.
Frequent BCOR aberrations in extranodal NK/T-Cell lymphoma, nasal type.
Genes Chromosomes Cancer, 55, 460-71 (2016)
I. Fukada, K. Araki, K. Kobayashi, T. Shibayama, S. Takahashi, R. Horii, F. Akiyama, T. Iwase, S. Ohno, K. Hatake, Y. Hozumi, N. Sata and Y. Ito.
Predictive factors and value of ypN+ after neoadjuvant chemotherapy in clinically lymph node-negative breast cancer.
PLoS One, 11, e0162616 (2016)
A. Goy, A. Forero, N. Wagner-Johnston, W. Christopher Ehmann, M. Tsai, K. Hatake, R. Ananthakrishnan, A. Volkert, E. Vandendries and M. Ogura.
A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy.
Br. J. Haematol., 174, 571-81 (2016)
A. Harada, M. Oguchi, Y. Terui, K. Takeuchi, M. Igarashi, T. Kozuka, K. Harada, T. Uno and K. Hatake.
Radiation therapy for localized duodenal low-grade follicular lymphoma.
J. Radiat. Res., 57, 412-417 (2016)
K. Hatake, T. Doi, H. Uetake, Y. Takahashi, Y. Ishihara and K. Shirao.
Bevacizumab safety in Japanese patients with colorectal cancer.
Jpn. J. Clin. Oncol, 46, 234-40 (2016)
K. Kobayashi, Y. Ito, M. Matsuura, I. Fukada, R. Horii, S. Takahashi, F. Akiyama, T. Iwase, Y. Hozumi, Y. Yasuda and K. Hatake.
Impact of immunohistological subtypes on the long-term prognosis of patients with metastatic breast cancer.
Surg. Today, 47, 821-6 (2016)
Y. Kusano, N. Nishimura, M. Yokoyama, Y. Terui and K. Hatake.
Gastric involvement, a rare site for extramedullary myeloma.
Ann. Hematol., 95, 663-4 (2016)
Y. Kusano, Y. Terui, N. Nishimura, M. Yokoyama, K. Ueda and K. Hatake.
Myelomatous meningitis: a case report.
Int. J. Hematol., 104, 149-50 (2016)
Y. Kusano, Y. Terui, K. Ueda and K. Hatake.
Epstein-Barr virus gastric ulcer associated with ruxolitinib.
Ann. Hematol., 95, 1741-2 (2016)
Y. Kusano, Y. Terui, K. Ueda and K. Hatake.
Klebsiella pneumoniae primary liver abscess associated with ruxolitinib.
Ann. Hematol., 95, 1561-2 (2016)
Y. Kusano, Y. Terui, M. Yokoyama and K. Hatake.
Lichenoid drug eruption associated with Bendamustine.
Blood Cancer J., 6, e438 (2016)
D. Maruyama, H. Nagai, N. Fukuhara, T. Kitano, T. Ishikawa, H. Shibayama, I. Choi, K. Hatake, T. Uchida, M. Nishikori, T. Kinoshita, Y. Matsuno, T. Nishikawa, S. Takahara and K. Tobinai.
Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma.
Cancer Sci., 107, 1785-90 (2016)
M. Ogura, K. Tobinai, K. Hatake, A. Davies, M. Crump, R. Ananthakrishnan, T. Ishibashi, M. L. Paccagnella, J. Boni, E. Vandendries and D. MacDonald.
Phase I study of inotuzumab ozogamicin combined with R-CVP for relapsed/refractory CD22+ B-cell non-Hodgkin lymphoma.
Clin. Cancer Res., 22, 4807-4816 (2016)
Y. Shigematsu, M. Matsuura, N. Nishimura, N. Tsuyama, K. Takeuchi, Y. Terui, N. Takeshima and K. Hatake.
Intravascular large B-cell lymphoma of bilateral ovaries and the uterus in an asymptomatic patient with a t(11;22)(q23;q11) constitutional translocation.
Intern. Med., 55, 3169-74 (2016)
K. Suzuki, A. Shinagawa, T. Uchida, M. Taniwaki, H. Hirata, K. Ishizawa, K. Matsue, Y. Ogawa, T. Shimizu, M. Otsuka, M. Matsumoto, S. Iida, Y. Terui, I. Matsumura, T. Ikeda, N. Takezako, Y. Ogaki, S. Midorikawa, V. Houck, A. Ervin-Haynes and T. Chou.
Lenalidomide and low-dose dexamethasone in Japanese patients with newly diagnosed multiple myeloma: a phase II study.
Cancer Sci., 107, 653-8 (2016)

このページのTOPへ

2015年

Ko JJ, Xie W, Kroeger N, Lee JL, Rini BI, Knox JJ, Bjarnason GA, Srinivas S, Pal SK, Yuasa T., Smoragiewicz M, Donskov F, Kanesvaran R, Wood L, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Choueiri TK, Heng DY.
The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol. 2015 Mar;16(3):293-300.
Yuasa T., Inoshita N, Saiura A, Yamamoto S, Urakami S, Masuda H, Fujii Y, Fukui I, Ishikawa Y, Yonese J.
Clinical outcome of patients with pancreatic metastases from renal cell cancer. BMC Cancer. 2015 15:46.
Uehara S, Yuasa T., Fujii Y, Yano A, Yamamoto S, Masuda H, Fukui I, Yonese J.
Prior administration of a non-steroidal anti-androgen failed to prevent the flare-up caused by a luteinizing hormone-releasing hormone agonist in a patient with metastatic prostate cancer. BMC Res Notes. 2015 Aug 5;8:335.
Yuasa T., Inoshita N, Tanaka H, Urakami S, Yamamoto S, Fujii Y, Masuda H, Fukui I, Ishikawa Y, Yonese J.
Surveillance policy for Japanese patients with stage I testicular germ cell cancer in the multi-detector computed tomography era. Int J Clin Oncol. 2015 Dec;20(6):1198-202.
Urakami S, Yuasa T., Yamamoto S, Sakura M, Tanaka H, Hayashi T, Uehara S, Inoue Y, Fujii Y, Masuda H, Fukui I, Yonese J.
Clinical response to induction chemotherapy predicts improved survival outcome in urothelial carcinoma with clinical lymph nodal metastasis treated by consolidative surgery. Int J Clin Oncol. 2015 Dec;20(6):1171-8.
Yuasa T..
Editorial comment on: p21-activated kinase 1 predicts recurrence and survival of patients with non-metastatic clear cell renal cell carcinoma. Int J Urol. 2015 May;22(5):453-4.
Fay AP, Xie WL, Lee LC, Harshman LC, Bjarnason GA, Knox SE, Wood L, Vaishamayan UN, Yuasa T., Tan MH, Rha SY, Donskov F, Agarwa N, Kollmannsberger CK, North SA, Rini BI, Choueiri TK, Heng DYC.
Characteristics of Long-term and Short-term Survivors of Metastatic Renal Cell Carcinoma Treated with Targeted Therapies: Results from the International mRCC Database Consortium. Clinical Genitourinary Cancer 2015 Apr;13(2):150-5.
Kyriakopoulos CE, Chittoria N, Choueiri TK, Kroeger N, Lee JL, Srinivas S, Knox JJ, Bjarnason GA, Ernst SD, Wood LA, Vaishampayan UN, Agarwal N, Pal SK, Kanesvaran R, Rha SY, Yuasa T., Donskov F, North SA, Heng DY, Rini BI.
Outcome of Patients With Metastatic Sarcomatoid Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer 2015 Apr;13(2):e79-85.
Yasuda Y, Fujii Y, Yuasa T., Yamamoto S, Yonese J, Fukui I.
Do testosterone levels have prognostic significance in patients with metastatic prostate cancer treated with combined androgen blockade? Int J Urol. 2015 Jan;22(1):132-3.
Nitta, H., Terui, Y., Yokoyama, M., Mishima, Y., Nishimura, N., Ueda, K., Kusano, Y., Tsuyama, N., Takeuchi, K., Kanda, Y., Hatake, K.
Absolute peripheral monocyte count at diagnosis predicts central nervous system relapse in diffuse large B-cell lymphoma.
Haematologica, 100, 87-90 (2015)
Nakayama, Y., Ito, Y., Tanabe, M., Takahashi, S., Hatake, K.
A combination of aprepitant, palonosetron, and dexamethasone prevents emesis associated with anthracycline-containing regimens for patients with breast cancer. A retrospective study.
Breast Cancer, 22, 177-184 (2015)
Roccaro, A.M., Mishima, Y., Sacco, A., Moschetta, M., Tai, Y.T., Shi, J., Zhang, Y., Reagan, M.R., Huynh, D., Kawano, Y., Sahin, I., Chiarini, M., Manier, S., Cea, M., Aljawai, Y., Glavey, S., Morgan, E., Pan, C., Michor, F., Cardarelli, P., Kuhne, M., Ghobrial, I.M.
CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation.
Cell Rep, 12, 622-635 (2015)
Suzuki, S., Matsusaka, S., Hirai, M., Shibata, H., Takagi, K., Mizunuma, N., Hatake, K.
A novel approach to detect KRAS/BRAF mutation for colon cancer: Highly sensitive simultaneous detection of mutations and simple pre-treatment without DNA extraction.
Int J Oncol, 47, 97-105 (2015)

このページのTOPへ

2014年

Yuasa T., Urakami S.
Decreased incidence of skeletal-related events in mRCC. Nature Reviews in Urology. 2014 Apr;11(4):193-4.
Mashima T, Soma-Nagae T, Migita T, Kinoshita R, Iwamoto A, Yuasa T., Yonese J, Ishikawa Y, Seimiya H.
TRIB1 supports prostate tumorigenesis and tumor-propagating cell survival by regulation of endoplasmic reticulum chaperone expression. Cancer Res. 2014 Sep 1;74(17):4888-97.
Heng DY, Wells JC, Rini BI, Beuselinck B, Lee JL, Knox JJ, Bjarnason GA, Pal SK, Kollmannsberger CK, Yuasa T., Srinivas S, Donskov F, Bamias A, Wood LA, Ernst DS, Agarwal N, Vaishampayan UN, Rha SY, Kim JJ, Choueiri TK.
Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. Eur Urol. 2014 Oct;66(4):704-10.
Tanaka H,Yuasa T., Fujii Y, Sakura M, Kitsukawa S, Urakami S, Yamamoto S, Masuda H, Fukui I, Yonese J.
First-line combination chemotherapy with cisplatin, etoposide, and ifosfamide for the treatment of disseminated germ cell cancer: re-evaluation in the granulocyte colony-stimulating factor era. Chemotherapy 2014 Oct;12(5):335-40.
Yuasa T..
Editorial Comment to Efficacies of traditional and alternative sunitinib treatment schedules in patients with metastatic renal cell carcinoma in a Japanese population. Int J Urol 2014 Oct;21(10):1069-70.
Isono T, Chano T, Kitamura A, Yuasa T..
Glucose Deprivation Induces G2/M Transition-Arrest and Cell Death in N-GlcNAc2-Modified Protein-Producing Renal Carcinoma Cells. PLoS One. 2014 May 5;9(5):e96168.
Harshman LC, Kroeger N, Rha SY, Donskov F, Wood L, Tantravahi SK, Vaishampayan U, Rini BI, Knox J, North S, Ernst S, Yuasa T., Srinivas S, Pal S, Heng DY, Choueiri TK.
First-Line Mammalian Target of Rapamycin Inhibition in Metastatic Renal Cell Carcinoma: An Analysis of Practice Patterns From the International Metastatic Renal Cell Carcinoma Database Consortium. Clin Genitourin Cancer. 2014 Oct;12(5):335-40.
Heng DY, Choueiri TK, Rini BI, Lee J, Yuasa T., Pal SK, Srinivas S, Bjarnason GA, Knox JJ, Mackenzie M, Vaishampayan UN, Tan MH, Rha SY, Donskov F, Agarwal N, Kollmannsberger C, North S, Wood LA.
Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol. 2014 Jan;25(1):149-54.
Yuasa T..
Editorial Comment to Localized non-conventional renal cell carcinoma: Prediction of clinical outcome according to histology. Int J Urol. 2014;21(4):364-5.
Ko JJ, Choueiri TK, Rini BI, Lee JL, Kroeger N, Srinivas S, Harshman LC, Knox JJ, Bjarnason GA, MacKenzie MJ, Wood L, Vaishampayan UN, Agarwal N, Pal SK, Tan MH, Rha SY, Yuasa T., Donskov F, Bamias A, Heng DY.
First-, second-, third-line therapy for mRCC: benchmarks for trial design from the IMDC. Br J Cancer. 2014 Apr 15;110(8):1917-22.
Schutz FA, Xie W, Donskov F, Sircar M, McDermott DF, Rini BI, Agarwal N, Pal SK, Srinivas S, Kollmannsberger C, North SA, Wood LA, Vaishampayan U, Tan MH, Mackenzie MJ, Lee JL, Rha SY, Yuasa T., Heng DY, Choueiri TK.
The Impact of Low Serum Sodium on Treatment Outcome of Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Cancer Database Consortium. Eur Urol. 2014 Apr;65(4):723-30.
Tsuchiya N, Yuasa T., Maita S, Narita S, Inoue T, Numakura K, Saito M, Satoh S, Yonese J, Habuchi T.
Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinoma. BMC Urology 2014, 14:26
Fujii Y, Yamamoto S, Yonese J, Masuda H, Urakami S, Kitsukawa S, Sakura M, Yuasa T., Kihara K, Fukui I.
The Processus Vaginalis Transection Method to Prevent Postradical Prostatectomy Inguinal Hernia: Long-term Results. Urology. 2014 Jan;83(1):247-52.
Kroeger N, Choueiri TK, Lee JL, Bjarnason GA, Knox JJ, Mackenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T., Donskov F, Agarwal N, Tan MH, Bamis A, Kollmannsberger CK, North SA, Rini BI, Heng DY.
Survival Outcome and Treatment Response of Patients with Late Relapse from Renal Cell Carcinoma in the Era of Targeted Therapy. Eur Urol. 2014 Jun;65(6):1086-92.
Urakami S, Fujii Y, Yamamoto S, Yuasa T., Kitsukawa S, Sakura M, Yano A, Saito K, Masuda H, Yonese J, Fukui I.
Phase II trial of first-line chemotherapy with gemcitabine, etoposide, and cisplatin for patients with advanced urothelial carcinoma. Urol Oncol. 2014 Jan;32(1):35.e1-7.
Kodama, T., Motoi, N., Ninomiya, H., Sakamoto, H., Kitada, K., Tsukaguchi, T., Satoh, Y., Nomura, K., Nagano, H., Ishii, N., Terui, Y., Hatake, K., Ishikawa, Y.
A novel mechanism of EML4-ALK rearrangement mediated by chromothripsis in a patient-derived cell Ll.
J Thorac Oncol, 9, 1638-1646 (2014)
Matsusaka, S., Kozuka, M., Takagi, H., Ito, H., Minowa, S., Hirai, M., Hatake, K.
A novel detection strategy for living circulating tumor cells using 5-aminolevulinic acid.
Cancer Lett, 355, 113-120 (2014)

このページのTOPへ

2013年

Kroeger N, Xie W,Lee JL,Bjarnason GA, Knox JJ, MacKenzie MJ, Wood L, Srinivas S, Vaishamayan UN, Rha SY, Pal SK, Yuasa T., Donskov F, Agarwal N, Kollmannsberger CK, Tan MH, North SA, Rini BI, Choueiri TK, Heng DYC.
Metastatic non clear cell renal cell carcinoma (nccRCC) treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium (IMDC) Criteria. Cancer 2013;119(16):2999-3006.
Yuasa T., Kitsukawa S, Sukegawa G, Yamamoto S, Kudo K, Miyazawa K, Kozuka T, Harada S, Yonese J.
Early onset recall pneumonitis during targeted therapy with sunitinib.BMC Cancer. 2013; 13:3.
Yasuda Y, Yuasa T., Yamamoto S, Urakami S, Ito M, Sukegawa G, Kitsukawa S, Fujii Y, Yonese J, Fukui I.
Evaluation of the RENAL nephrometry scoring system in adopting nephron-sparing surgery for cT1 renal cancer Urologia Int 2013;90(2):179-83.
Yasuda Y, Fujii Y, Yuasa T., Kitsukawa S, Urakami S, Yamamoto S, Yonese J, Takahashi S, Fukui I.
Possible improvement of survival with use of zoledronic acid in patients with bone metastases from renal cell carcinoma. Int J Clin Oncol. 2013 Oct;18(5):877-83.
Yasuda Y, Saito K, Yuasa T., Kitsukawa S, Urakami S, Yamamoto S, Yonese J, Takahashi S, Fukui I.
Prognostic impact of pretreatment C-reactive protein for patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors. Int J Clin Oncol. 2013 Oct;18(5):884-9.
Doi, T., Hamaguchi, T., Shirao, K., Chin, K., Hatake, K., Noguchi, K., Otsuki, T., Mehta, A., Ohtsu, A.
Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial.
Int J Clin Oncol, 18, 87-95 (2013)
Kuboki, Y., Matsusaka, S., Minowa, S., Shibata, H., Suenaga, M., Shinozaki, E., Mizunuma, N., Ueno, M., Yamaguchi, T., Hatake, K.
Circulating tumor cell (CTC) count and epithelial growth factor receptor expression on CTCs as biomarkers for cetuximab efficacy in advanced colorectal cancer.
Anticancer Res, 33, 3905-3910 (2013)
Nakayama, Y., Ito, Y., Tanabe, M., Takahashi, S.
Diverticular bleeding of the colon during combination chemotherapy with bevacizumab and paclitaxel for recurrent breast cancer.
Case Rep Oncol, 6, 50-54 (2013)
Nakayama, Y., Ito, Y., Tanabe, M., Takahashi, S., Hatake, K.
A combination of aprepitant, palonosetron, and dexamethasone prevents emesis associated with anthracycline-containing regimens for patients with breast cancer. A retrospective study.
Breast Cancer, in press (2013)
Ogura, M., Hatake, K., Tobinai, K., Uchida, T., Suzuki, T., Terui, Y., Yokoyama, M., Maruyama, D., Mori, M., Jewell, R.C., Katsura, K., Hotta, T.
Phase I study of ofatumumab, a human anti-CD20 antibody, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Jpn J Clin Oncol, 43, 466-475 (2013)
Ogura, M., Tobinai, K., Hatake, K., Uchida, T., Suzuki, T., Kobayashi, Y., Mori, M., Terui, Y., Yokoyama, M., Hotta, T.
Phase I study of obinutuzumab (GA101) in Japanese patients with relapsed or refractory B-cell non-Hodgkin lymphoma.
Cancer Sci, 104, 105-110 (2013)
Suzuki, K., Terui, Y., Nishimura, N., Mishima, Y., Sakajiri, S., Yokoyama, M., Takahashi, S., Tsuyama, N., Takeuchi, K., Hatake, K.
Prognostic value of C-reactive protein, lactase dehydrogenase and anemia in recurrent or refractory aggressive lymphoma.
Jpn J Clin Oncol, 43, 37-44 (2013)
Suzuki, K., Terui, Y., Yokoyama, M., Ueda, K., Nishimura, N., Mishima, Y., Sakajiri, S., Tsuyama, N., Takeuchi, K., Hatake, K.
Prognostic value of high thymidine kinase activity in previously untreated diffuse large B-cell lymphoma patients treated by R-CHOP.
Leuk Lymphoma, 54, 2412-2417 (2013)
Takagi, S., Sato, S., Oh-Hara, T., Takagi, M., Koike, S., Mishima, Y., Hatake, K., Fujita, N.
Platelets promote tumor growth and metastasis via direct interaction between Aggrus/Podoplanin and CLEC-2.
PLoS One, 8, e73609 (2013)
Ueda, K., Terui, Y., Yokoyama, M., Sakajiri, S., Nishimura, N., Tsuyama, N., Takeuchi, K., Hatake, K.
Non-gastric advanced mucosa-associated lymphoid tissue (MALT) lymphoma has worse prognosis than gastric MALT lymphoma even when treated with rituximab-containing chemotherapy.
Leuk Lymphoma, 54, 1928-1933 (2013)
Yokoyama, M., Terui, Y., Takeuchi, K., Nara, E., Nakano, K., Ueda, K., Nishimura, N., Mishima, Y., Sakajiri, S., Tsuyama, N., Ozawa, K., Hatake, K.
Infusion rate escalation study of rituximab in patients with CD20+ B-cell lymphomas: A single institution analysis in Japan.
ISRN Oncol, 2013:863909 (2013)

このページのTOPへ

2012年

Yuasa T., Yamamoto S, Urakami S, Fukui I, Yonese J.
Denosumab: a new option in the treatment of bone metastases from urological cancers. OncoTargets and Therapy.2012: 5; 221-9.
Yuasa T., Fujii Y, Takahashi S, Fukui I, Yonese J.
Molecular targeted therapies for patients with metastatic renal cell cancer. Translational Med 2012.
Maita S, Yuasa T., Tsuchiya N, Mitobe M, Narita S, Horikawa Y, Hatake K, Fukui I, Kimura S, Maekawa T, Habuchi T.
Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function. Int J Cancer 2012;130:677-84.
Yuasa T., Tsuchiya N, Horikawa Y, Narita S, Inoue T, Urakami S, Yamamoto S, Yonese J, Takahashi S, Hatake K, Fukui I. Habuchi T.
Clinical Efficacy and Prognostic Factors for Overall Survival in Japanese Patients with Metastatic Renal Cell Cancer Treated with Sunitinib. BJU int. 2012 May;109(9):1349-54.
Nakano K, Takahashi S, Yuasa T., Nishimura N, Mishima Y, Sakajiri S, Yokoyama M, Tsuyama N, Ishikawa Y, Hatake K.
Feasibility and efficacy of combined Cisplatin and irinotecan chemotherapy for poorly differentiated neuroendocrine carcinomas. Jpn J Clin Oncol. 2012 Aug;42(8):697-703.
Sugawara S, Togashi Y, Kuroda N, Sakata S, Hatano S, Asaka R, Yuasa T., Yonese J, Kitagawa M, Mano H, Ishikawa Y, Takeuchi K.
Identification of ALK fusions in renal cancer: Large-scale immunohistochemical screening by intercalated antibody-enhanced polymer method. Cancer 2012 Sep 15;118(18):4427-36.
Narita S, Tsuchiya N, Yuasa T., Maita S, Obara T, Numakura K, Tsuruta H, Saito M, Inoue T, Horikawa Y, Satoh S, Habuchi T.
Outcome, clinical prognostic factors and genetic predictors of adverse reactions of intermittent combination chemotherapy with docetaxel, estramustine phosphate and carboplatin for castration-resistant prostate cancer. Int J Clin Oncol 2012 Jun;17(3):204-11
Hosonaga, M., Ito, Y., Tokudome, N., Takahashi, S., Iwase, T., Hatake, K.
A lower dose of docetaxel at 60 mg/m(2) could be continued longer for controlling peripheral edema in patients with metastatic breast cancer.
Breast Cancer, 19, 329-334 (2012)
Ito, Y.
Should we treat minimal breast cancer lesions?
Breast Cancer, 19, 93-94 (2012)
Ito, Y., Iwase, T., Hatake, K.
Eradication of breast cancer cells in patients with distant metastasis: the finishing touches?
Breast Cancer, 19, 206-2011 (2012)
Ito, Y., Suenaga, M., Hatake, K., Takahashi, S., Yokoyama, M., Onozawa, Y., Yamazaki, K., Hironaka, S., Hashigami, K., Hasegawa, H., Takenaka, N., Boku, N.
Safety, efficacy and pharmacokinetics of neratinib (HKI-272) in Japanese patients with advanced solid tumors: A phase 1 dose-escalation study.
Jpn J Clin Oncol, 42, 278-286 (2012)
Maita, S., Yuasa, T., Tsuchiya, N., Mitobe, Y., Narita, S., Horikawa, Y., Hatake, K., Fukui, I., Kimura, S., Maekawa, T., Habuchi, T.
Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function.
Int J Cancer, 130, 677-684 (2012)
Mishima, Y., Terui, Y., Kuniyoshi, R., Matsusaka, S., Mikuniya, M., Kojima, K., Hatake, K.
High reproducible ADCC analysis revealed a competitive relation between ADCC and CDC and differences between FcgammaRllla polymorphism.
Int Immunol, 24, 477-483 (2012)
Takahashi, S., Iwase, T., Kohno, N., Ishikawa, T., Taguchi, T., Takahashi, M., Horiguchi, J., Nakamura, S., Hozumi, Y., Fukunaga, M., Noguchi, S.
Efficacy of zoledronic acid in postmenopausal Japanese women with early breast cancer receiving adjuvant letrozole: 12-month results.
Breast Cancer Res Treat, 133, 685-693 (2012)
Yuasa, T., Tsuchiya, N., Urakami, S., Horikawa, Y., Narita, S., Inoue, T., Saito, M., Yamamoto, S., Yonese, J., Fukui, I., Nakano, K., Takahashi, S., Hatake, K., Habuchi, T.
Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
BJU Int, 109, 1394-1354 (2012)

このページのTOPへ

2011年

Yuasa T., Takahashi S, Hatake K, Yonese J, Fukui I.
Biomarkers to Predict Response to Sunitinib Therapy and Prognosis in Metastatic Renal Cell Cancer. Cancer Science2011;102:1949-57.
Yuasa T., Urakami S, Yamamoto S, Yonese J, Takahashi S, Hatake K, Fukui I.
Treatment Outcome and Prognostic Factors of the Patients with Renal Cell Cancer Bone Metastasis. Clin Exp Metastasis 2011; 28: 405-11.
Yuasa T., Urakami S, Yamamoto S, Yonese J, Nakano K, Kodaira M, Takahashi S, Hatake K, Inamura K, Ishikawa Y, Fukui I.
Tumor Size is a Potential Predictor of the Response to Tyrosine Kinase Inhibitors in Renal Cell Cancer. Urology 2011; 77: 831-5.
Urakami S, Yonese J, Yamamoto S, Yuasa T., Kitsukawa S, Numao N, Kubo Y, Ito M, Sukegawa G, Yasuda Y, Ishikawa Y, Fukui I.
Outcome of Antegrade Radical Prostatectomy with Intended Wide Resection in Prostate Cancer Patients with a Preoperative Serum PSA Level >100 ng/ml. Urol Int. 2011;87:175-81.
Ito M, Saito K, Yasuda Y, Sukegawa G, Kubo Y, Numao N, Kitsukawa S, Urakami S, Yuasa T., Yamamoto S, Yonese J, Fukui I.
Prognostic Impact of C-reactive Protein for Determining Overall Survival of Patients With Castration-resistant Prostate Cancer Treated With Docetaxel. Urology. 2011;78:1131-5.
Numakura K, Tsuchiya N, Yuasa T., Saito M, Obara T, Tsuruta H, Narita S, Horikawa Y, Satoh S, Habuchi T.
A case study of metastatic Xp11.2 translocation renal cell carcinoma effectively treated with sunitinib. Int J Clin Oncol 2011;16:577-80.
Saito M, Tsuchiya N, Maita S, Numakura K, Obara T, Tsuruta H, Kumazawa T, Inoue T, Narita S, Horikawa Y, Yuasa T., Satoh S, Habuchi T.
What Is the Most Preferred Wound Site for Laparoscopic Donor Nephrectomy?: A Questionnaire Assessment. J Laparoendosc Adv Surg Tech A 2011; 21: 511-5.
Fukutomi, A., Hatake, K., Matsui, K., Sakajiri, S., Hirashima, T., Tanii, H., Kobayashi, K., Yamamoto, N.
A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors.
Invest New Drugs, in press (2011)
Hosonaga, M., Ito, Y., Tokudome, N., Takahashi, S., Iwase, T., Hatake, K.
A lower dose of docetaxel at 60 mg/m(2) could be continued longer for controlling peripheral edema in patients with metastatic breast cancer.
Breast Cancer, in press (2011)
Ito, Y., Iwase, T., Hatake, K.
Eradication of breast cancer cells in patients with distant metastasis: the finishing touches?
Breast Cancer, in press (2011)
Ito, Y., Nagasaki, K., Miki, Y., Iwase, T., Akiyama, F., Matsuura, M., Horii, R., Makita, M., Tokudome, N., Ushijima, M., Yoshimoto, M., Takahashi, S., Noda, T., Hatake, K.
Prospective randomized phase II study determines the clinical usefulness of genetic biomarkers for sensitivity to primary chemotherapy with paclitaxel in breast cancer.
Cancer Sci, 102, 130-136 (2011)
Maita, S., Yuasa, T., Tsuchiya, N., Mitobe, Y., Narita, S., Horikawa, Y., Hatake, K., Fukui, I., Kimura, S., Maekawa, T., Habuchi, T.
Antitumor effect of sunitinib against skeletal metastatic renal cell carcinoma through inhibition of osteoclast function.
Int J Cancer, (2011)
Matsusaka, S., Mishima, Y., Suenaga, M., Terui, Y., Kuniyoshi, R., Mizunuma, N., Hatake, K.
Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab.
Cancer, 117, 4026-4032 (2011)
Okanami, Y., Ito, Y., Watanabe, C., Iijima, K., Iwase, T., Tokudome, N., Takahashi, S., Hatake, K.
Incidence of chemotherapy-induced amenorrhea in premenopausal patients with breast cancer following adjuvant anthracycline and taxane.
Breast Cancer, (2011)
Oyama, M., Nagashima, T., Suzuki, T., Kozuka-Hata, H., Yumoto, N., Shiraishi, Y., Ikeda, K., Kuroki, Y., Gotoh, N., Ishida, T., Inoue, S., Kitano, H., Okada-Hatakeyama, M.
Integrated quantitative analysis of the phosphoproteome and transcriptome in tamoxifen-resistant breast cancer.
J Biol Chem, 286, 818-829 (2011)
Suenaga, M., Matsusaka, S., Ueno, M., Yamamoto, N., Shinozaki, E., Mizunuma, N., Yamaguchi, T., Hatake, K.
Predictors of the efficacy of FOLFIRI plus bevacizumab as second-line treatment in metastatic colorectal cancer patients.
Surg Today, 41, 1067-1074 (2011)
Suenaga, M., Matsusaka, S., Watanabe, T., Kuboki, Y., Shinozaki, E., Chin, K., Mizunuma, N., Ueno, M., Yamaguchi, T., Hatake, K.
How do we apply adjuvant FOLFOX to Japanese patients with curatively resected colorectal cancer?
Asia Pac J Clin Oncol, 7, 129-135 (2011)
Takahashi, S., Miyazaki, M., Okamoto, I., Ito, Y., Ueda, K., Seriu, T., Nakagawa, K., Hatake, K.
Phase I study of dasatinib (BMS-354825) in Japanese patients with solid tumors.
Cancer Sci, 102, 2058-2064 (2011)
Tokudome, N., Ito, Y., Takahashi, S., Kobayashi, K., Taira, S., Tsutsumi, C., Oto, M., Oba, M., Inoue, K., Kuwayama, A., Masumura, K., Nakayama, Y., Watanabe, C., Hatake, K.
Detection of circulating tumor cells in peripheral blood of heavily treated metastatic breast cancer patients.
Breast Cancer, 18, 195-202 (2011)
Yuasa, T., Takahashi, S., Hatake, K., Yonese, J., Fukui, I.
Biomarkers to predict response to sunitinib therapy and prognosis in metastatic renal cell cancer.
Cancer Sci, in press (2011)
Yuasa, T., Tsuchiya, N., Urakami, S., Horikawa, Y., Narita, S., Inoue, T., Saito, M., Yamamoto, S., Yonese, J., Fukui, I., Nakano, K., Takahashi, S., Hatake, K., Habuchi, T.
Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
BJU Int, (2011)
Yuasa, T., Urakami, S., Yamamoto, S., Yonese, J., Nakano, K., Kodaira, M., Takahashi, S., Hatake, K., Inamura, K., Ishikwa, Y., Fukui, I.
Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer.
Urology, 77, 831-835 (2011)
Yuasa, T., Urakami, S., Yamamoto, S., Yonese, J., Saito, K., Takahashi, S., Hatake, K., Fukui, I.
Treatment outcome and prognostic factors in renal cell cancer patients with bone metastasis.
Clin Exp Metastasis, 28, 405-411 (2011)

このページのTOPへ

2010年

Tomita Y, Shinohara N, Yuasa T., Fujimoto H, Niwakawa M, Mugiya S, Miki T, Uemura H, Nonomura N, Takahashi M, Hasegawa Y, Agata N, Houk B, Naito S, Akaza H.
Overall Survival and Updated Results from a Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma. Jpn J Clin Oncol. 2010; 40: 1166-72.
Kodaira M, Takahashi S, Takeuchi K,Yuasa T., Saotome T, Yonese J, Fukui I, Hatake K.
Erythema multiforme induced by sorafenib for metastatic renal cell carcinoma in Japanese patients. Ann Oncol. 2010; 21, 1563-5.
Ma Z, Tsuchiya N, Yuasa T., Huang M, Obara T, Narita S, Horikawa Y, Tsuruta H, Saito M, Satoh S, Ogawa O, Habuchi T.
Clinical Significance of Polymorphism and Expression of Chromogranin A and Endothelin-1 in Prostate Cancer. J Urol. 2010; 184, 1182-8.
Yuasa T., Maita S, Tsuchiya N, Ma Z, Narita S, Horikawa Y, Yamamoto S, Yonese J, Fukui I, Takahashi S, Hatake K, Habuchi T.
Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients. Urology 2010; 75, 1131-7.
Uemura H, Shinohara N, Yuasa T., Tomita Y, Fujimoto H, Niwakawa M, Mugiya S, Miki T, Nonomura N, Takahashi M, Hasegawa Y, Agata N, Houk B, Naito S, Akaza H.
A Phase II Study of Sunitinib in Japanese Patients with Metastatic Renal Cell Carcinoma: Insights into the Treatment, Efficacy and Safety. Jpn J Clin Oncol. 2010; 40: 194-202.
Asai, H., Yokoyama, M., Terui, Y., Ennishi, D., Takeuchi, K., Hatake, K.
Is statin use really associated with efficacy of rituximab?
J Clin Oncol, 28, e424-425; author reply e427-428 (2010)
Ennishi, D., Asai, H., Maeda, Y., Shinagawa, K., Ikeda, K., Yokoyama, M., Terui, Y., Takeuchi, K., Yoshino, T., Matsuo, K., Hatake, K., Tanimoto, M.
Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.
Ann Oncol, 21, 1217-1221 (2010)
Hijioka, S., Chin, K., Seto, Y., Yamamoto, N., Hatake, K.
Eight-year survival after advanced gastric cancer treated with S-1 followed by surgery.
World J Gastroenterol, 16, 2824-2827 (2010)
Ito, Y., Nagasaki, K., Miki, Y., Iwase, T., Akiyama, F., Matsuura, M., Horii, R., Makita, M., Tokudome, N., Ushijima, M., Yoshimoto, M., Takahashi, S., Noda, T., Hatake, K.
Prospective randomized phase II study determines the clinical usefulness of genetic biomarkers for sensitivity to primary chemotherapy with paclitaxel in breast cancer.
Cancer Sci, 102, 130-136 (2010)
Kodaira, M., Takahashi, S., Takeuchi, K., Yuasa, T., Saotome, T., Yonese, J., Fukui, I., Hatake, K.
Sorafenib-induced erythema multiforme for metastatic renal cell carcinoma.
Ann Oncol, 21, 1563-1565 (2010)
Kodaira, M., Takahashi, S., Yamada, S., Ueda, K., Mishima, Y., Takeuchi, K., Yamamoto, N., Ishikawa, Y., Yokoyama, M., Saotome, T., Terui, Y., Hatake, K.
Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy.
Ann Oncol, 21, 1163-1167 (2010)
Matsusaka, S., Chin, K., Ogura, M., Suenaga, M., Shinozaki, E., Mishima, Y., Terui, Y., Mizunuma, N., Hatake, K.
Circulating tumor cells as a surrogate marker for determining response to chemotherapy in patients with advanced gastric cancer.
Cancer Sci, 101, 1067-1071 (2010)
Suenaga, M., Mizunuma, N., Kobayashi, K., Shinozaki, E., Matsusaka, S., Chin, K., Kuboki, Y., Ichimura, T., Ozaka, M., Ogura, M., Fujiwara, Y., Matsueda, K., Konishi, F., Hatake, K.
Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab.
Med Oncol, 27, 807-814 (2010)
Suenaga, M., Mizunuma, N., Kobayashi, K., Shinozaki, E., Matsusaka, S., Chin, K., Kuboki, Y., Ichimura, T., Ozaka, M., Ogura, M., Fujiwara, Y., Matsueda, K., Konishi, F., Hatake, K.
Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab.
Med Oncol, 27, 807-814 (2010)
Uemura, H., Shinohara, N., Yuasa, T., Tomita, Y., Fujimoto, H., Niwakawa, M., Mugiya, S., Miki, T., Nonomura, N., Takahashi, M., Hasegawa, Y., Agata, N., Houk, B., Naito, S., Akaza, H.
A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety.
Jpn J Clin Oncol, 40, 194-202 (2010)
Yuasa, T., Maita, S., Tsuchiya, N., Ma, Z., Narita, S., Horikawa, Y., Yamamoto, S., Yonese, J., Fukui, I., Takahashi, S., Hatake, K., Habuchi, T.
Relationship between bone mineral density and androgen-deprivation therapy in Japanese prostate cancer patients.
Urology, 75, 1131-1137 (2010)

このページのTOPへ

2009年

Wang W, Yuasa T., Tsuchiya N, Ma Z, Maita S, Narita S, Kumazawa T, Inoue T, Tsuruta H, Horikawa Y, Saito M, Hu W, Ogawa O, Habuchi T.
The novel tumor-suppressor Mel-18 in prostate cancer: its functional polymorphism, expression, and clinical significance. Int J Cancer. 2009; 125: 2836-43.
Yuasa T., Sato K, Ashihara E, Takeuchi M, Maita S, Tsuchiya N, Habuchi T, Maekawa T, Kimura S.
Intravesical administration of gammadelta T cells successfully prevents the growth of bladder cancer in the murine model. Cancer Immunol Immunother. 2009; 58: 493-502.
Yuasa T..
Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival. Int J Urol. 2009;16: 731-2.
Tsuchiya N, Narita S, Kumazawa T, Inoue T, Ma Z, Tsuruta H, Saito M, Horikawa Y, Yuasa T., Satoh S, Ogawa O, Habuchi T.
Clinical significance of a single nucleotide polymorphism and allelic imbalance of matrix metalloproteinase-1 promoter region in prostate cancer. Oncol Rep. 2009; 22: 493-9.
Kumazawa T, Tsuchiya N, Saito M, Inoue T, Narita S, Horikawa Y, Yuasa T., Satoh S, Kato T, Nanjyo H, Habuchi T.
Cystoprostatectomy as a treatment of prostate cancer involving the bladder neck. Urol Int. 2009; 83: 141-5.
Ennishi, D., Yokoyama, M., Terui, Y., Asai, H., Sakajiri, S., Mishima, Y., Takahashi, S., Komatsu, H., Ikeda, K., Takeuchi, K., Tanimoto, M., Hatake, K.
Soluble interleukin-2 receptor retains prognostic value in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP (RCHOP) therapy.
Ann Oncol, 20, 526-533 (2009)
Ito, Y., Osaki, Y., Tokudome, N., Sugihara, T., Takahashi, S., Iwase, T., Hatake, K.
Efficacy of S-1 in heavily pretreated patients with metastatic breast cancer: cross-resistance to capecitabine.
Breast Cancer, 16, 126-131 (2009)
Mishima, Y., Sugimura, N., Matsumoto-Mishima, Y., Terui, Y., Takeuchi, K., Asai, S., Ennishi, D., Asai, H., Yokoyama, M., Kojima, K., Hatake, K.
An imaging-based rapid evaluation method for complement-dependent cytotoxicity discriminated clinical response to rituximab-containing chemotherapy.
Clin Cancer Res, 15, 3624-3632 (2009)
Mori, M., Nakamoto, S., Akifuji, Y., Tanaka, T., Komatsu, N., Hatake, K., Ozawa, K.
Familial sideroblastic anemia associated with cardiac atrial septal defect.
Am J Hematol, 84, 451-452 (2009)
Morota, M., Gomi, K., Kozuka, T., Chin, K., Matsuura, M., Oguchi, M., Ito, H., Yamashita, T.
Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma.
Int J Radiat Oncol Biol Phys, 75, 122-128 (2009)
Osako, T., Ito, Y., Ushijima, M., Takahashi, S., Tokudome, N., Sugihara, T., Iwase, T., Matsuura, M., Hatake, K.
Predictive factors for efficacy of capecitabine in heavily pretreated patients with metastatic breast cancer.
Cancer Chemother Pharmacol, 63, 865-871 (2009)
Suenaga, M., Mizunuma, N., Chin, K., Matsusaka, S., Shinozaki, E., Oya, M., Ueno, M., Yamaguchi, T., Muto, T., Konishi, F., Hatake, K.
Chemotherapy for Small-Bowel Adenocarcinoma at a Single Institution.
Surgery Today, 39, 27-31 (2009)
Tanabe, M., Ito, Y., Tokudome, N., Sugihara, T., Miura, H., Takahashi, S., Seto, Y., Iwase, T., Hatake, K.
Possible use of combination chemotherapy with mitomycin C and methotrexate for metastatic breast cancer pretreated with anthracycline and taxanes.
Breast Cancer, 16, 301-306 (2009)
Terui, Y., Mishima, Y., Sugimura, N., Kojima, K., Sakurai, T., Kuniyoshi, R., Taniyama, A., Yokoyama, M., Sakajiri, S., Takeuchi, K., Watanabe, C., Takahashi, S., Ito, Y., Hatake, K.
Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma.
Clin Cancer Res, 15, 2523-2530 (2009)
Wang, W., Yuasa, T., Tsuchiya, N., Ma, Z., Maita, S., Narita, S., Kumazawa, T., Inoue, T., Tsuruta, H., Horikawa, Y., Saito, M., Hu, W., Ogawa, O., Habuchi, T.
The novel tumor-suppressor Mel-18 in prostate cancer: its functional polymorphism, expression and clinical significance.
Int J Cancer, 125, 2836-2843 (2009)
Yuasa, T.
Editorial Comment to docetaxel-based combination chemotherapy with zoledronic acid and prednisone in hormone refractory prostate cancer: Factors predicting response and survival.
Int J Urol, 16, 731-732 (2009)
Yuasa, T., Sato, K., Ashihara, E., Takeuchi, M., Maita, S., Tsuchiya, N., Habuchi, T., Maekawa, T., Kimura, S.
Intravesical administration of γδ T cells successfully prevents the growth of bladder cancer in the murine model.
Cancer Immunol Immunother, 58, 493-502 (2009)

このページのTOPへ

2008年

Chin, K., Baba, S., Hosaka, H., Ishiyama, A., Mizunuma, N., Shinozaki, E., Suenaga, M., Kozuka, T., Seto, Y., Yamamoto, N., Hatake, K.
Irinotecan plus cisplatin for therapy of small-cell carcinoma of the esophagus: report of 12 cases from single institution experience.
Jpn J Clin Oncol, 38, 426-431 (2008)
Ennishi, D., Takeuchi, K., Yokoyama, M., Asai, H., Mishima, Y., Terui, Y., Takahashi, S., Komatsu, H., Ikeda, K., Yamaguchi, M., Suzuki, R., Tanimoto, M., Hatake, K.
CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy.
Ann Oncol, 19, 1921-1926 (2008)
Ennishi, D., Terui, Y., Yokoyama, M., Mishima, Y., Takahashi, S., Takeuchi, K., Ikeda, K., Tanimoto, M., Hatake, K.
Increased incidence of interstitial pneumonia by CHOP combined with rituximab.
Int J Hematol, 87, 393-397 (2008)
Ennishi, D., Terui, Y., Yokoyama, M., Mishima, Y., Takahashi, S., Takeuchi, K., Okamoto, H., Tanimoto, M., Hatake, K.
Monitoring serum hepatitis C virus (HCV) RNA in patients with HCV-infected CD20-positive B-cell lymphoma undergoing rituximab combination chemotherapy.
Am J Hematol, 83, 59-62 (2008)
Ennishi, D., Yokoyama, M., Terui, Y., Takeuchi, K., Ikeda, K., Tanimoto, M., Hatake, K.
Does rituximab really induce hepatitis C virus reactivation?
J Clin Oncol, 26, 4695-4696; author reply 4696 (2008)
Osako, T., Ito, Y., Takahashi, S., Tokudome, N., Iwase, T., Hatake, K.
Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer.
Cancer Chemother Pharmacol, 62, 159-164 (2008)
Saito, F., Matsusaka, S., Takahashi, Y., Wakabayashi, I.
Enhancement of nitric oxide synthase induction in alveolar macrophages by in vivo administration of docetaxel.
Eur J Pharmacol, 580, 425-430 (2008)
Suenaga, M., Mizunuma, N., Shinozaki, E., Matsusaka, S., Chin, K., Muto, T., Konishi, F., Hatake, K.
Management of allergic reactions to oxaliplatin in colorectal cancer patients.
J Support Oncol, 6, 373-378 (2008)
Suenaga, M., Mizunuma, N., Shouji, D., Shinozaki, E., Matsusaka, S., Chin, K., Oya, M., Yamaguchi, T., Muto, T., Hatake, K.
Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan.
J Gastroenterol, 43, 842-848 (2008)
Tokudome, N., Ito, Y., Hatake, K., Toi, M., Sano, M., Iwata, H., Sato, Y., Saeki, T., Aogi, K., Takashima, S.
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II and pharmacokinetic study in Japan.
Anticancer Drugs, 19, 753-759 (2008)

このページのTOPへ

2007年

Boku, N., Ohtsu, A., Hyodo, I., Shirao, K., Miyata, Y., Nakagawa, K., Tamura, T., Hatake, K., Tanigawara, Y.
Phase II study of oxaliplatin in japanese patients with metastatic colorectal cancer refractory to fluoropyrimidines.
Jpn J Clin Oncol, 37, 440-445 (2007)
Ennishi, D., Yokoyama, M., Mishima, Y., Watanabe, C., Terui, Y., Takahashi, S., Takeuchi, K., Ikeda, K., Tanimoto, M., Hatake, K.
Rituximab plus CHOP as an initial chemotherapy for patients with disseminated MALT lymphoma.
Leuk Lymphoma, 48, 2241-2243 (2007)
Hatake, K., Tokudome, N., Ito, Y.
5. Tanstuzumab treatment for breast cancer.
Intern Med, 46, 149-150 (2007)
Hatake, K., Tokudome, N., Ito, Y.
Next generation molecular targeted agents for breast cancer: focus on EGFR and VEGFR pathways.
Breast Cancer, 14, 132-149 (2007)
Ito, Y., Tokudome, N., Sugihara, T., Takahashi, S., Hatake, K.
Does lapatinib, a small-molecule tyrosine kinase inhibitor, constitute a breakthrough in the treatment of breast cancer?
Breast Cancer, 14, 156-162 (2007)
Matsusaka, S., Yamasaki, H., Fukushima, M., Wakabayashi, I.
Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer.
Chemotherapy, 53, 36-41 (2007)
Mishima, Y., Terui, Y., Sugimura, N., Matsumoto-Mishima, Y., Rokudai, A., Kuniyoshi, R., Hatake, K.
Continuous treatment of bestatin induces anti-angiogenic property in endothelial cells.
Cancer Sci, 98, 364-372 (2007)
Mitsuhashi, J., Tsukahara, S., Suzuki, R., Oh-hara, Y., Nishi, S., Hosoyama, H., Katayama, K., Noguchi, K., Minowa, S., Shibata, H., Ito, Y., Hatake, K., Aiba, K., Takahashi, S., Sugimoto, Y.
Retroviral integration site analysis and the fate of transduced clones in an MDR1 gene therapy protocol targeting metastatic breast cancer.
Hum Gene Ther, 18, 895-906 (2007)
Morimoto, H., Takahashi, M., Shiba, Y., Izawa, A., Ise, H., Hongo, M., Hatake, K., Motoyoshi, K., Ikeda, U.
Bone marrow-derived CXCR4+ cells mobilized by macrophage colony-stimulating factor participate in the reduction of infarct area and improvement of cardiac remodeling after myocardial infarction in mice.
Am J Pathol, 171, 755-766 (2007)
Osako, T., Ito, Y., Morimatsu, A., Tada, K., Sakurai, N., Takahashi, S., Akiyama, F., Iwase, T., Hatake, K.
Flare-up of dermatomyositis along with recurrence of breast cancer.
Breast J, 13, 200-202 (2007)
Osako, T., Ito, Y., Takahashi, S., Tokudome, N., Iwase, T., Hatake, K.
Intermittent capecitabine monotherapy with lower dose intensity in heavily pretreated patients with metastatic breast cancer.
Tumori, 93, 129-132 (2007)
Shiba, Y., Takahashi, M., Yoshioka, T., Yajima, N., Morimoto, H., Izawa, A., Ise, H., Hatake, K., Motoyoshi, K., Ikeda, U.
M-CSF accelerates neointimal formation in the early phase after vascular injury in mice: the critical role of the SDF-1-CXCR4 system.
Arterioscler Thromb Vasc Biol, 27, 283-289 (2007)
Takahashi, S., Aiba, K., Ito, Y., Hatake, K., Nakane, M., Kobayashi, T., Minowa, S., Shibata, H., Mitsuhashi, J., Tsukahara, S., Ishikawa, E., Suzuki, R., Tsuruo, T., Sugimoto, Y.
Pilot study of MDR1 gene transfer into hematopoietic stem cells and chemoprotection in metastatic breast cancer patients.
Cancer Sci, 98, 1609-1616 (2007)
Utsubo-Kuniyoshi, R., Terui, Y., Mishima, Y., Rokudai, A., Sugimura, N., Kojima, K., Sonoda, Y., Kasahara, T., Hatake, K.
MEK-ERK is involved in SUMO-1 foci formation on apoptosis.
Cancer Sci, 98, 569-576 (2007)
Yokota, A., Kimura, S., Masuda, S., Ashihara, E., Kuroda, J., Sato, K., Kamitsuji, Y., Kawata, E., Deguchi, Y., Urasaki, Y., Terui, Y., Ruthardt, M., Ueda, T., Hatake, K., Inui, K., Maekawa, T.
INNO-406, a novel BCR-ABL/Lyn dual tyrosine kinase inhibitor, suppresses the growth of Ph+ leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity.
Blood, 109, 306-314 (2007)

このページのTOPへ

2006年

Ennishi, D., Sezaki, N., Senoo, T., Terui, Y., Hatake, K., Hino, N.
A case of acute promyelocytic leukemia during gefitinib treatment.
Int J Hematol, 84, 284-285 (2006)
Furukawa, K., Ito, Y., Takahashi, S., Sawaki, M., Mizunuma, N., Horikoshi, N., Kasumi, F., Akiyama, F., Sakamoto, G., Furukawa, K., Tajiri, T., Hatake, K.
Efficacy and safety of combined trastuzumab and Paclitaxel therapy as a second-line treatment in women with metastatic breast cancer: a single institutional experience.
Breast Cancer, 13, 329-333 (2006)
Hyodo, I., Shirao, K., Doi, T., Hatake, K., Arai, Y., Yamaguchi, K., Tamura, T., Takemiya, S., Takiuchi, H., Nakagawa, K., Mishima, H.
A phase II Study of the global dose and schedule of capecitabine in Japanese patients with metastatic colorectal cancer.
Jpn J Clin Oncol, 36, 410-417 (2006)
Kurihara, R., Tohyama, Y., Matsusaka, S., Naruse, H., Kinoshita, E., Tsujioka, T., Katsumata, Y., Yamamura, H.
Effects of peripheral cannabinoid receptor ligands on motility and polarization in neutrophil-like HL60 cells and human neutrophils.
J Biol Chem, 281, 12908-12918 (2006)
Matsusaka, S., Wakabayashi, I.
Enhancement of vascular smooth muscle cell migration by urotensin II.
Naunyn Schmiedebergs Arch Pharmacol, 373, 381-386 (2006)
Mishima, Y., Terui, Y., Takeuchi, K., Nagasaki, E., Yokoyama, M., Mizunuma, N., Takahashi, S., Yamada, K., Fukunaga, T., Yamamoto, J., Yamaguchi, T., Kato, Y., Hatake, K.
Simultaneously occurring chronic myelogenous leukemia andgastrointestinal stromal tumors treated with imatinib.
Targeted Oncology, 1, 168-171 (2006)
Rokudai, A., Terui, Y., Kuniyoshi, R., Mishima, Y., Aizu-Yokota, E., Sonoda, Y., Kasahara, T., Hatake, K.
Differential Regulation of Eotaxin-1/CCL11 and Eotaxin-3/CCL26 Production by the TNF-α and IL-4 Stimulated Human Lung Fibroblast.
Biol Pharm Bull, 29, 1102-1109 (2006)
Sano, M., Tokuda, Y., Noguchi, S., Aogi, K., Saeki, T., Tabei, T., Hatake, K., Fujii, H.
A phase-I clinical study of a combination therapy of vinorelbine and capecitabine in patients with advanced/recurrent breast cancer.
Gan To Kagaku Ryoho, 33, 1091-1097 (2006)
Sawaki, M., Ito, Y., Akiyama, F., Tokudome, N., Horii, R., Mizunuma, N., Takahashi, S., Horikoshi, N., Imai, T., Nakao, A., Kasumi, F., Sakamoto, G., Hatake, K.
High prevalence of HER-2/neu and p53 overexpression in inflammatory breast cancer.
Breast Cancer, 13, 172-178 (2006)
Suenaga, M., Oya, M., Ueno, M., Yamamoto, J., Yamaguchi, T., Mizunuma, N., Hatake, K., Kato, Y., Muto, T.
Anal canal carcinoma with Pagetoid spread: report of a case.
Surg Today, 36, 666-669 (2006)
Tada, K., Ito, Y., Takahashi, S., Iijima, K., Miyagi, Y., Nishimura, S., Takahashi, K., Makita, M., Iwase, T., Yoshimoto, M., Kasumi, F.
Tolerability and safety of classic cyclophosphamide, methotrexate, and fluorouracil treatment in Japanese patients with early breast cancer.
Breast Cancer, 13, 279-283 (2006)
Takahashi, S., Ito, Y., Hatake, K., Sugimoto, Y.
Gene therapy for breast cancer. --Review of clinical gene therapy trials for breast cancer and MDR1 gene therapy trial in Cancer Institute Hospital.
Breast Cancer, 13, 8-15 (2006)
Terui, Y., Sakurai, T., Mishima, Y., Sugimura, N., Sasaoka, C., Kojima, K., Yokoyama, M., Mizunuma, N., Takahashi, S., Ito, Y., Hatake, K.
Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab.
Cancer Sci, 97, 72-79 (2006)

このページのTOPへ